Future studies, powered for different disease severities and for patients presenting different comorbidities are needed to determine whether inflammasome signaling proteins are associated with disease severity and whether comorbidities affect inflammasome protein levels associated with COVID-19. This evidence concerns the gene PROS1 and COVID-19.